Table 3. Conflicting results between Seeplex and Anyplex assays (n=9) were resolved using MEMO sequencing, FNA cytology, and post-thyroidectomy histological analyses.
| Case No. | Seeplex | Anyplex (Ct)* | MEMO sequencing | FNA cytology | Histology |
|---|---|---|---|---|---|
| 70 | Positive | Negative (-) | Negative | Benign | Follicular carcinoma† |
| 24 | Negative | Positive (28.26) | Negative | Benign | NT |
| 138 | Negative | Positive (32.60) | Negative | Benign | NT‡ |
| 33 | Negative | Positive (30.50) | Negative | AUS | NT |
| 185 | Negative | Positive (25.13) | Positive | Suspicious for malignancy | Papillary microcarcinoma |
| 47 | Negative | Positive (25.28) | Positive | Papillary thyroid carcinoma | Papillary microcarcinoma |
| 175 | Negative | Positive (26.68) | Positive | Papillary thyroid carcinoma | Papillary microcarcinoma |
| 133 | Negative | Positive (26.37) | Positive | Papillary thyroid carcinoma | Papillary microcarcinoma |
| 155 | Negative | Positive (26.64) | Positive | Papillary thyroid carcinoma | Papillary microcarcinoma |
*Ct values <33 were considered positive; †Minimally-invasive follicular carcinoma; ‡Post-thyroidectomy histological findings were unavailable; however, follow-up FNA cytology results after 18 months indicated this case was benign.
Abbreviations: Ct, cycle threshold; MEMO, mutant enrichment with 3'-modified oligonucleotide; FNA, fine needle aspirates; NT, not tested; AUS, atypia of undetermined significance.